Akebia therapeutics reports inducement grants under nasdaq listing rule 5635(c)(4)

Cambridge, mass. , june 3, 2024 /prnewswire/ -- akebia therapeutics, inc. (nasdaq: akba), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 4 newly-hired employees options to purchase an aggregate of 76,000 shares of akebia's common stock on may 31, 2024, as inducements material to such employee entering into employment with akebia.
NDAQ Ratings Summary
NDAQ Quant Ranking